Company: RGNT
Filing Date: 2025-01-27
Form Type: DRS/A
Source: 0001213900-25-006676
Chunk: 103

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-01-27
Form: DRS/A
Chunk 103
---
37.8 million. We anticipate
that we will continue to generate tax losses for the foreseeable future and that we will be able to carry forward these tax losses indefinitely
to future taxable years. Accordingly, we do not expect to pay taxes in Israel until we have taxable income after the full utilization
of our carry forward tax losses.

Results of Operations

Our results of operations
have varied in the past and can be expected to vary in the future due to numerous factors. We believe that period-to-period comparisons
of our operating results are not necessarily meaningful and should not be relied upon as indications of future performance.

Our results of operations
for the years ended December 31, 2023 and 2022 and the six months ended June 30, 2024 and 2023 were as follows:

| (in thousands of USD, except share and per share data)                                                             |     | 2023 |   Year Ended 
 December 31, |     | 2022 |        |     | 2024 | Six Months Ended 
         June 30, |   |     | 2023 |        |
|:-------------------------------------------------------------------------------------------------------------------|:----|:-----|-------------:|:----|:-----|-------:|:----|:-----|-----------------:|:--|:----|:-----|-------:|
| Statements of Operations Data:                                                                                     |     |      |              |     |      |        |     |      |                  |   |     |      |        |
| Research and ‌development ‌expenses                                                                                |     |      |          806 |     |      |    971 |     |      |           (2,170 | ) |     |      |    414 |
| General and ‌administrative ‌expenses                                                                              |     |      |        1,125 |     |      |    436 |     |      |              297 |   |     |      |    791 |
| Operating ‌loss                                                                                                    |     |      |        1,931 |     |      |  1,407 |     |      |           (1,873 | ) |     |      |  1,205 |
| Finance expenses (income), net                                                                                     |     |      |        2,201 |     |      |     42 |     |      |           (5,334 | ) |     |      |  2,081 |
| Net ‌ loss